| 研究成果の概要 |
I developed a novel assay to identify compounds which could selectively kill tumour cells with high levels of NRF2. Thus, I identified two different classes of compounds, geldanamycin-derived HSP90 inhibitors, and the DNA damaging agent mitomycin C, which both displayed NRF2-dependent toxicity.
|
| 研究成果の学術的意義や社会的意義 |
As there are no approved drugs which can be used to treat patients with NRF2-dependent tumours, there is an urgent unmet clinical need to identify such drugs. In this project, I identified the chemotherapy drug mitomycin C to be an ideal candidate for drug repositioning to NRF2-dependent tumours.
|
